Mary Bouxsein, PhD

Mary Bouxsein is the Maurice E Mueller Professor of Orthopedic Surgery at Harvard Medical School and co-lead on the landmark Study to Advance BMD as a Regulatory Endpoint (SABRE), which aims to change the paradigm of drug development in osteoporosis by gaining approval for bone mineral density as a surrogate endpoint for fractures via the FDA Biomarker Qualification Program. Dr. Bouxsein also co-directs the Center for Musculoskeletal Research and is a faculty member in the combined Harvard-MIT Health Sciences and Technology Program. Dr. Bouxsein received her PhD in Mechanical Engineering from Stanford University and completed postdoctoral training at Harvard Medical School. Her research focuses on understanding the biomechanical underpinnings of skeletal fragility in osteoporosis and other bone diseases, including bone loss due to spaceflight. Her work spans both preclinical and large clinical studies (e.g., Framingham Osteoporosis Study, MrOS study).

She has served in several leadership roles, including the President of the American Society for Bone and Mineral Research, Associate Editor of the Journal of Bone and Mineral Research, Board Member of the International Osteoporosis Foundation and member of the Advisory Council for the National Institute of Arthritis, Skin and Musculoskeletal Diseases at the National Institutes of Health. Dr. Bouxsein has published over 435 peer-reviewed articles and 30 book chapters and is a sought-after speaker both nationally and internationally.